EP0215925A4 - Supplemental calcium addition unit. - Google Patents

Supplemental calcium addition unit.

Info

Publication number
EP0215925A4
EP0215925A4 EP19860902230 EP86902230A EP0215925A4 EP 0215925 A4 EP0215925 A4 EP 0215925A4 EP 19860902230 EP19860902230 EP 19860902230 EP 86902230 A EP86902230 A EP 86902230A EP 0215925 A4 EP0215925 A4 EP 0215925A4
Authority
EP
European Patent Office
Prior art keywords
solution
calcium
ampule
amino acid
intravenously
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19860902230
Other languages
German (de)
French (fr)
Other versions
EP0215925A1 (en
Inventor
John C Miller
Robin Dawe
Albert Stone
Shanker L Gupta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baxter International Inc
Original Assignee
Baxter Travenol Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Travenol Laboratories Inc filed Critical Baxter Travenol Laboratories Inc
Publication of EP0215925A1 publication Critical patent/EP0215925A1/en
Publication of EP0215925A4 publication Critical patent/EP0215925A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/06Aluminium, calcium or magnesium; Compounds thereof, e.g. clay

Definitions

  • Amino acid in solutions suitable for injection are used with critically ill patients to provide nu- trition.
  • the injectable amino acid solutions are sold without certain electrolytes which may be needed by a patient. In that circumstance, it becomes desirable for the doctor to add appropriate electrolytes to the container of amino acid solution immediately prior to intravenous administration to the patient.
  • electrolytes often added are phos ⁇ phate and calcium, as well as other physiologica] elec- trolytes.
  • Amino acid solutions have been provided in glass bottles, where they may have a relatively low pH.
  • small amounts of phosphate and calcium may be added to the amino acid solution without the risk of forming a precipitate, because the pH of amino acid solutions currently sold in bottles is sufficiently low to prevent the precipitation of, for example, dibasic calcium phosphate.
  • a supplemental calcium addition unit for administering dissolved calcium to a container of phosphate-containing intravenous amino acid solution.
  • the unit comprises an ampule, plus means carried on the ampule for facilitatingsubstantially aseptic fluid flow connection with the interior of said container.
  • This may constitute any of various conventional means for transferring an ampule of material in aseptic manner to a larger container.
  • the ampule may carry a needle-pierceable latex wall, which may be penetratedin conventional manner with a needle and syringe.
  • the ampule contains a solution of intravenously metabolizable calcium compound at a pH of 2 to 5.5. Accordingly, sufficient acidity may be provided by the contents of the ampule, so that when the calcium c ⁇ pound is added to phosphate-containing intravenous amino acid solution, no precipitation takes place.
  • the solution inside the ampule may typically con- tain from 5 to 25 weight percent of calcium gluconate, a known metabolizable calcium compound, plus sufficient gluconic acid to provide to the solution a preferredpH of 3 to 4.
  • the solution may also contain from 4 to 6 mg. of calcium d-saccharate per ml. of solution whichis present, as a precipitation inhibitor as well as a source of added calcium and as a stabilizer.
  • metabolizable calcium which may be used in the supplemental calcium addition unit include calcium chloride, calcium acetate, calcium lactate, cal ⁇ cium ascorbate, or calcium succinate.
  • acids besides gluconic acid may also be used to provide a pH within the desired range, for example acetic acid, hydrochloric acid, ascorbic acid, lactic ac- id, succinic acid, or any other desired acid which would be suitable for use in an injectable solution at the appropriate pH.
  • the solution may be prepared by adding the desired amount of calcium gluconate (preferably 10 to 20 percent by weight) to rapidly boiling water for in ⁇ jection, which may be present in about 80 percent of the total volume of solution required, with constantstirring.
  • the desired amount of calcium gluconate preferably 10 to 20 percent by weight
  • the desired amount of calcium gluconate preferably 10 to 20 percent by weight
  • the desired amount of calcium gluconate preferably 10 to 20 percent by weight
  • the desired amount of calcium gluconate preferably 10 to 20 percent by weight
  • rapidly boiling water for in ⁇ jection which may be present in about 80 percent of the total volume of solution required, with constantstirring.
  • calcium d-saccharate may be added. Twice this amount of calcium d-saccharate may be added for a 15 percent solution of calcium gluconate.
  • the solution becomes clear after 2 or 3 minutes of continuous boiling.
  • the solution is then allowed to cool to room temperature.
  • 50 percent gluconic acid may be added incrementally until the pH of the solution is, preferably, 3.4-3.5.
  • gluconic acid For 10 percent calcium gluconate solution, about 56 mg./ml. of gluconic acid is required to obtain this pH.
  • the resulting solution is then adjusted tothe total volume required by the addition, if necessary, of up to about 10 or 20 percent of its volume of water for injec ⁇ tion.
  • the solution is then filtered through a 0.2 micron filter to prevent nucleation by crystallites or contam- inants in the solution.
  • the solution is then filled into 50 ml. glass ampules, stoppered with a conventional ampule closure, and autoclaved for 35 minutes.
  • ampules may be trans ⁇ ferred by injection needle using normal aseptic technique into a flexible, collapsible container of amino acid injection solution containing dissolved phosphate and other electrolytes, the amino acid injection solution typically having a pH of 6 to 8, without formation of any precipitate.
  • a typical pH value for such amino acid injection solutions is 7.5.
  • a typical glass ampule 10 containing a solution of this invention is shown.
  • the ampule is closed with a conventional latex needle-piercable dia ⁇ phragm 12, and is autoclaved before use.

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Materials For Medical Uses (AREA)
  • Treating Waste Gases (AREA)

Abstract

A supplemental calcium addition unit for providing calcium to a container of phosphate-containing intravenous amino-acid solution. The unit comprises an ampule, plus means on the ampule for facilitating substantially aseptic fluid flow connection with the interior of the container, for example a needle pierceable latex membrane. The ampule comtains a solution of an intravenously metabolizable calcium compound typically at a pH of 2 to 5.5.

Description

SUPPLEMENTAL CALCIUM ADDITION UNIT
TECHNICAL FIELD
Amino acid in solutions suitable for injection are used with critically ill patients to provide nu- trition. For example, TRAVASOL *= (amino acid) Injection is currently sold by Travenol Laboratories, Inc. of Deerfield, Illinois. Typically, the injectable amino acid solutions are sold without certain electrolytes which may be needed by a patient. In that circumstance, it becomes desirable for the doctor to add appropriate electrolytes to the container of amino acid solution immediately prior to intravenous administration to the patient. Among the electrolytes often added are phos¬ phate and calcium, as well as other physiologica] elec- trolytes.
Amino acid solutions have been provided in glass bottles, where they may have a relatively low pH. In this circumstance, small amounts of phosphate and calcium may be added to the amino acid solution without the risk of forming a precipitate, because the pH of amino acid solutions currently sold in bottles is sufficiently low to prevent the precipitation of, for example, dibasic calcium phosphate.
It has been deemed desirable to provide amino acid solutions in collapsible plastic containers to ob¬ tain the many advantages which collapsible plastic con¬ tainers can provide over glass containers. These advan¬ tages have caused glass containers to be substantially replaced by collapsible plastic containers in most other large volume parenteral products. However, technical factors have required that the amino acid solutions which are marketed in collapsible containers must have a pH of about 6.0-8.0 (and typically at least 6.5), which tends to be higher than the pH of amino acid so- lutions sold in glass containers, which usually have a pH of about 5 to 6.5.
In this circumstance, when one has added phosphate to the amino acid solution, and one attempts to add a standard unit of calcium gluconate injection, USP, which has a pH of 6.0-8.2, there is a risk that a precipitate of typically dibasic calcium phosphate will form. The formation of such a precipitate renders the solution unfit for intravenous administration to a patient.
Also, when larger amounts of calcium and phosphate are required by a patient, for example a pediatric patient, there arises a risk that a precipitate will form even in lower pH amino acid injection solutions.
By this invention, a way is provided in which more metabolizable calcium and phosphate can be added to amino acid formulations without the risk of causing precipitation.
DESCRIPTION OF THE INVENTION
By this invention a supplemental calcium addition unit is provided for administering dissolved calcium to a container of phosphate-containing intravenous amino acid solution. The unit comprises an ampule, plus means carried on the ampule for facilitatingsubstantially aseptic fluid flow connection with the interior of said container. This may constitute any of various conventional means for transferring an ampule of material in aseptic manner to a larger container. For example the ampule may carry a needle-pierceable latex wall, which may be penetratedin conventional manner with a needle and syringe.
The ampule contains a solution of intravenously metabolizable calcium compound at a pH of 2 to 5.5. Accordingly, sufficient acidity may be provided by the contents of the ampule, so that when the calcium cαπpound is added to phosphate-containing intravenous amino acid solution, no precipitation takes place. The solution inside the ampule may typically con- tain from 5 to 25 weight percent of calcium gluconate, a known metabolizable calcium compound, plus sufficient gluconic acid to provide to the solution a preferredpH of 3 to 4. The solution may also contain from 4 to 6 mg. of calcium d-saccharate per ml. of solution whichis present, as a precipitation inhibitor as well as a source of added calcium and as a stabilizer.
Other forms of metabolizable calcium which may be used in the supplemental calcium addition unit include calcium chloride, calcium acetate, calcium lactate, cal¬ cium ascorbate, or calcium succinate.
Other acids besides gluconic acid may also be used to provide a pH within the desired range, for example acetic acid, hydrochloric acid, ascorbic acid, lactic ac- id, succinic acid, or any other desired acid which would be suitable for use in an injectable solution at the appropriate pH.
For the manufacture of a specific example of the invention, the solution may be prepared by adding the desired amount of calcium gluconate (preferably 10 to 20 percent by weight) to rapidly boiling water for in¬ jection, which may be present in about 80 percent of the total volume of solution required, with constantstirring. In the case where a 10 percent solution of calcium glu- conate is being prepared five mg. , per ml. , of calcium d-saccharate may be added. Twice this amount of calcium d-saccharate may be added for a 15 percent solution of calcium gluconate.
The solution becomes clear after 2 or 3 minutes of continuous boiling. The solution is then allowed to cool to room temperature. Following this, 50 percent gluconic acid may be added incrementally until the pH of the solution is, preferably, 3.4-3.5. For 10 percent calcium gluconate solution, about 56 mg./ml. of gluconic acid is required to obtain this pH.
The resulting solution is then adjusted tothe total volume required by the addition, if necessary, of up to about 10 or 20 percent of its volume of water for injec¬ tion. The solution is then filtered through a 0.2 micron filter to prevent nucleation by crystallites or contam- inants in the solution. The solution is then filled into 50 ml. glass ampules, stoppered with a conventional ampule closure, and autoclaved for 35 minutes.
The contents of one of these ampules may be trans¬ ferred by injection needle using normal aseptic technique into a flexible, collapsible container of amino acid injection solution containing dissolved phosphate and other electrolytes, the amino acid injection solution typically having a pH of 6 to 8, without formation of any precipitate. A typical pH value for such amino acid injection solutions is 7.5.
In the drawing, a typical glass ampule 10 containing a solution of this invention is shown. The ampule is closed with a conventional latex needle-piercable dia¬ phragm 12, and is autoclaved before use. If it is desired to use other calcium compounds than calcium gluconate, it is generally desirable to use the acid corresponding to the anion of the calcium com¬ pound for pH control. For example, one may use acetic acid for pH control with a calcium acetate solution, or ascorbic acid with a calcium ascorbate solution.

Claims

WHAT IS CLAIMED IS:
1. A supplemental calcium addition unit for pro¬ viding calcium to a container of intravenous amino acid solution, which comprises: an ampule, and means carried on said ampule for facilitating substantially aseptic fluid flow connection with the interior of said container, said ampule con¬ taining a solution of an intravenously metabolizable calcium compound at a pH of 2 to 5.5.
2. The unit of Claim 1 in which said solution contains 5 to 25 weight percent calcium gluconate and sufficient gluconic acid to provide to the solution a pH of 3 to 4.
3. The unit of Claim 2 which also contains from 4 to 6 g. of calcium d-saccharate per ml. of solution.
4. A supplemental calcium addition unit for pro¬ viding calcium to a flexible collapsible container of phosphate-containing intravenous amino acid solution, which comprises: an ampule, and means carried on said ampule for facilitating substantially aseptic fluid flow connection with the interior of said flexible collapsible container, said ampule containing a solution of an intravenous metabolizable calcium compound at a pH of 2 to 5.5.
5. The unit of Claim 4 which also contains from 4 to 6 mg. of calcium d-saccharate per ml. of solution.
6. The unit of Claim 5 in which said solution contains a mixture of 5 to 20 weight per cent calcium gluconate and sufficient gluconic acid to provide to the solution a pH of 3 to 4. 7. The method which comprises transferring in substantially aseptic manner the contents of an ampule which contains a solution of an intravenously metabo¬ lizable calcium compound at a pH of 2 to 5.5 into a con- tainer of intravenous amino acid solution, whereby the calcium compound remains in solution even when phos¬ phate is present.
8. The method of Claim 7 in which said container of amino acid solution is initially at a pH of at least 6.5.
9. The method of Claim 7 in which said calcium containing solution contains 5 to 25 weight per cent calcium gluconate and sufficient gluconic acid to pro¬ vide to the solution a pH of 3 to 4.
10. The method of Claim 7 in which said ampule also contains from 4 to 6 mg. of calcium d-saccharate per ml. of solution present.
11. For use as an additive to intravenous amino acid solutions, an aqueous solution of an intravenously metabolizable calcium compound at a pH of 2 to 5.5.
12. The solution of Claim 11 which contains 5 to 25 percent of calcium gluconate and sufficient gluconic acid to provide to the solution a pH of 3 to 4.
13. The solution of Claim 12 which also contains from 4 to 6 mg. of calcium d-saccharate per ml. of solu¬ tion.
14. The method which comprises adding a solution of an intravenously metabolizable calcium compound having a pH of 2 to 5.5 to an amino acid solution having a pH of 6 to 8, whereby the formation of a precipitate is prevented.
15. The method of Claim 14 in which said intra¬ venous amino acid solution contains an intravenously metabolizable phosphate compound.
16. The method of Claim 15 in which said amino acid solution is carried in a flexible, collapsible plastic container.
17. The method of Claim 16 in which said solution of intravenously metabolizable calcium compound is added to the amino acid solution under substantially aseptic conditions.
18. The method of Claim 17 in which said solution of intravenously metabolizable calcium compound contains
5 to 25 weight percent of calcium gluconate and sufficient gluconic acid to provide to said solution a pH of 3 to 4.
19. The method of Claim 18 in which said solution of intravenously metabolizable calcium compound also con¬ tains from 4 to 6 mg. of calcium d-saccharate per ml. of solution.
EP19860902230 1985-03-27 1986-03-24 Supplemental calcium addition unit. Withdrawn EP0215925A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71643285A 1985-03-27 1985-03-27
US716432 1985-03-27

Publications (2)

Publication Number Publication Date
EP0215925A1 EP0215925A1 (en) 1987-04-01
EP0215925A4 true EP0215925A4 (en) 1987-10-26

Family

ID=24877971

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19860902230 Withdrawn EP0215925A4 (en) 1985-03-27 1986-03-24 Supplemental calcium addition unit.

Country Status (5)

Country Link
EP (1) EP0215925A4 (en)
JP (1) JPS62502261A (en)
AU (1) AU5628386A (en)
WO (1) WO1986005688A1 (en)
ZA (1) ZA862326B (en)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3621094A (en) * 1968-04-05 1971-11-16 Smith Kline French Lab Concentrated aqueous liquid antacid compositions containing certain phosphate and gluconate salts
CA1017249A (en) * 1973-12-19 1977-09-13 Chemo Drug Company Injectable electrolyte solutions
JPS5632411A (en) * 1979-08-27 1981-04-01 Tomita Seiyaku Kk Preparation of perfusion liquid for artificial kidney dialysis
US4308255A (en) * 1980-03-24 1981-12-29 Haemophor Corporation Balanced oncotic pressure fluid
US4410321A (en) * 1982-04-06 1983-10-18 Baxter Travenol Laboratories, Inc. Closed drug delivery system

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
No relevant documents have been disclosed. *
See also references of WO8605688A1 *

Also Published As

Publication number Publication date
WO1986005688A1 (en) 1986-10-09
JPS62502261A (en) 1987-09-03
AU5628386A (en) 1986-10-23
ZA862326B (en) 1986-11-26
EP0215925A1 (en) 1987-04-01

Similar Documents

Publication Publication Date Title
JP3980200B2 (en) Peritoneal dialysis solution
NO161204B (en) PROCEDURE FOR PREPARING AN INSULIN SOLUTION.
CA1170990A (en) Stabilized insulin preparations and method for their production
CN106822175A (en) A kind of sodium acid carbonate ringer's injection and preparation method thereof
DE60215129T2 (en) ESMOLOL-CONTAINING PREPARATIONS
Lenz et al. Calcium and phosphate solubility in neonatal parenteral nutrient solutions containing Aminosyn-PF or TrophAmine
Watson Piggyback compatibility of antibiotics with pediatric parenteral nutrition solutions
Mackay et al. The solubility of calcium and phosphate in two specialty amino acid solutions
WO1986005688A1 (en) Supplemental calcium addition unit
Soges Bettner et al. Effects of pH, temperature, concentration, and time on particle counts in lipid‐containing total parenteral nutrition admixtures
US5650421A (en) Premixed famotidine formulation
JPH03135918A (en) Immune-activating agent
SE463804B (en) AN APPLICABLE PHARMACEUTICAL COMPOSITION OF WINE ADDITIONAL SALTS
NO864743L (en) SUPPLEMENTARY CALCIUM ADDITIVE UNIT.
JPH06135852A (en) Urinastatin injection
JP4575659B2 (en) Injection
JPH0469341A (en) Sugar electrolytic solution for tpn
US6187818B1 (en) Prostaglandins formulation and process
JP5623682B2 (en) Trace element formulation
CN102949413B (en) Method for preparing invert sugar and electrolytes injection
SU1395327A1 (en) Infusion solution for correcting metabolic alkalosis "sorbamin"
CN100333728C (en) Compound electrolytic fructose injection
Filler Total parenteral feeding of infants
Kirkpatrick et al. Effect of retrograde aminophylline administration on calcium and phosphate solubility in neonatal total parenteral nutrient solutions
JPH0283327A (en) Glucose electrolyte preparation for high calorie infusion

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19861125

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

RBV Designated contracting states (corrected)

Designated state(s): BE CH DE FR GB IT LI NL SE

A4 Supplementary search report drawn up and despatched

Effective date: 19871026

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19891003

RIN1 Information on inventor provided before grant (corrected)

Inventor name: GUPTA, SHANKER, L.

Inventor name: STONE, ALBERT

Inventor name: MILLER, JOHN, C.

Inventor name: DAWE, ROBIN